Technical Analysis for SXTP - 60 Degrees Pharmaceuticals, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| 20 DMA Support | Bullish | 3.14% | |
| Wide Bands | Range Expansion | 3.14% | |
| Crossed Above 20 DMA | Bullish | 3.14% | |
| NR7 | Range Contraction | 3.14% | |
| NR7-2 | Range Contraction | 3.14% | |
| Wide Bands | Range Expansion | 3.14% | |
| 20 DMA Resistance | Bearish | 9.07% | |
| NR7 | Range Contraction | 9.07% | |
| Doji - Bullish? | Reversal | 9.07% | |
| Wide Bands | Range Expansion | 9.07% |
| Alert | Time |
|---|---|
| 20 DMA Support | about 1 hour ago |
| 10 DMA Support | about 1 hour ago |
| Rose Above 10 DMA | about 1 hour ago |
| Down 5% | about 2 hours ago |
| Down 3% | about 2 hours ago |
Get a Trading Sidekick!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 02/28/2024
60 Degrees Pharmaceuticals, Inc. operates as a specialty pharmaceutical company that engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19; Tafenoquine for fungal lung infections, tick-borne diseases, candidiasis, and other infectious and non-infectious diseases; and Celgosivir for respiratory viruses and dengue. The company was founded in 2010 and is based in Washington, District of Columbia.
Sector: Healthcare
Industry: Biotechnology
Keywords: Pharmaceutical Infectious Diseases Infection Malaria Covid 19 Dengue Epidemiology Tropical Diseases Candidiasis Dengue Fever Tick Borne Diseases Treatment Of Infectious Diseases Vaccine Preventable Diseases
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Pharmaceutical Infectious Diseases Infection Malaria Covid 19 Dengue Epidemiology Tropical Diseases Candidiasis Dengue Fever Tick Borne Diseases Treatment Of Infectious Diseases Vaccine Preventable Diseases
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 18.36 |
| 52 Week Low | 0.7015 |
| Average Volume | 80,931 |
| 200-Day Moving Average | 2.38 |
| 50-Day Moving Average | 1.06 |
| 20-Day Moving Average | 0.89 |
| 10-Day Moving Average | 0.96 |
| Average True Range | 0.11 |
| RSI (14) | 46.81 |
| ADX | 15.54 |
| +DI | 19.67 |
| -DI | 15.92 |
| Chandelier Exit (Long, 3 ATRs) | 0.81 |
| Chandelier Exit (Short, 3 ATRs) | 1.03 |
| Upper Bollinger Bands | 1.07 |
| Lower Bollinger Band | 0.72 |
| Percent B (%b) | 0.57 |
| BandWidth | 39.94 |
| MACD Line | -0.03 |
| MACD Signal Line | -0.05 |
| MACD Histogram | 0.0122 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 1.03 | ||||
| Resistance 3 (R3) | 1.03 | 0.98 | 1.01 | ||
| Resistance 2 (R2) | 0.98 | 0.95 | 0.99 | 1.01 | |
| Resistance 1 (R1) | 0.95 | 0.94 | 0.93 | 0.96 | 1.00 |
| Pivot Point | 0.91 | 0.91 | 0.90 | 0.91 | 0.91 |
| Support 1 (S1) | 0.88 | 0.88 | 0.86 | 0.88 | 0.84 |
| Support 2 (S2) | 0.83 | 0.86 | 0.84 | 0.83 | |
| Support 3 (S3) | 0.80 | 0.83 | 0.83 | ||
| Support 4 (S4) | 0.81 |
